Navtemadlin Shows Efficacy, Safety in Relapsed/Refractory Myelofibrosis; Navtemadlin yields improvements in symptom score reductions ad spleen volume reduction among patients with relapsed/refractory myelofibrosis.

Press/Media

Period12 Dec 2024

Media coverage

2

Media coverage

  • TitleNavtemadlin Shows Efficacy, Safety in Relapsed/Refractory Myelofibrosis; Navtemadlin yields improvements in symptom score reductions ad spleen volume reduction among patients with relapsed/refractory myelofibrosis.
    Media name/outletCancerNetwork
    Country/TerritoryUnited States
    Date12/12/24
    PersonsJohn Mascarenhas
  • TitleNavtemadlin Shows Efficacy, Safety in Relapsed/Refractory Myelofibrosis
    Media name/outletCancernetwork.com
    Country/TerritoryUnited States
    Date12/12/24
    URLct.moreover.com/?a=55529046545&p=1gw&v=1&x=x8t81e2cfGA9iQvhZH0p7g
    PersonsJohn Mascarenhas